Strategic collaborations provide expanded
opportunities to apply PTC's scientific approach to additional therapeutic areas, access to development and
commercialization capabilities and significant financial resources.
|
CV Therapeutics — Exclusive research collaboration and licensing arrangement for the development of orally bioavailable small molecules through the application of PTC's proprietary GEMS (Gene Expression Modulation by Small-molecules) technology.
|
|
Cystic Fibrosis Foundation — A grant for up to $25 million in support of key Phase 2b clinical trials for PTC124 in nonsense mutation cystic fibrosis.
|
|
Muscular Dystrophy Association (MDA) — $1.5 million grant to support the development of PTC124 for the treatment of nonsense mutation Duchenne muscular dystrophy.
|
|
Parent Project Muscular Dystrophy (PPMD) — Support for preclinical development of PTC124 for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) and a collaboration to discover new drugs to treat DMD called Project Catalyst.
|
|
Pfizer Inc. - An exclusive research collaboration and licensing agreement for the development of pharmaceuticals through the application of PTC’s GEMS (Gene Expression Modulation by Small-molecules) technology.
|
|
Schering-Plough Corporation — $200 million collaboration for the development and commercialization of the compounds in the hepatitis C program.
|
|
Spinal Muscular Atrophy Foundation — $1.6 million grant to support discovery of new treatments for spinal muscular atrophy.
|